Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors

Ripretinib (Qinlock, Deciphera Pharmaceuticals) is indicated for 'the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib'.

The dosage schedule is available in the summary of product characteristics for ripretinib.

The list price of ripretinib is £18,400 per 30‑day supply (excluding VAT; company submission). This is based on a 150‑mg dose once daily (3 x 50‑mg tablets).

The company has a commercial arrangement. This makes ripretinib available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, Deciphera Pharmaceuticals' Carbon Reduction Plan for UK carbon emissions is published on ONP Pharma's (the parent company) website.